Servier to Acquire Day One Biopharmaceuticals in Merger

Day One Biopharmaceuticals ( (DAWN) ) has issued an update.

On March 6, 2026, Servier Pharmaceuticals LLC and Day One Biopharmaceuticals entered into a definitive merger agreement under which Servier will acquire all outstanding Day One shares for $21.50 in cash per share, valuing the company at approximately $2.5 billion. The all-cash tender offer, representing a premium of about 68% to Day One’s prior close and 86% to its one-month VWAP, is not subject to a financing condition and will be followed by a second-step merger once customary conditions, including majority tender and U.S. antitrust clearance, are met.

Day One’s board has unanimously deemed the transaction fair, recommended that shareholders tender their shares and agreed to customary non-solicitation and termination provisions, including an $87.7 million break fee under certain circumstances. For Servier, the deal is intended to strengthen its rare oncology franchise and targeted therapy pipeline, particularly in pediatric low-grade glioma, while giving Day One investors a substantial premium and positioning the combined group as a more prominent player in pediatric and rare oncology markets.

The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.

Spark’s Take on DAWN Stock

According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.

The score is held back primarily by persistent losses and heavy cash burn despite strong gross margins and low leverage. Offsetting this, technicals are bullish with a multi-timeframe uptrend, and the latest earnings call supports growth with reiterated 2026 guidance and strong commercial/payer metrics, though concentration and safety/gross-to-net headwinds remain.

To see Spark’s full report on DAWN stock, click here.

More about Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Brisbane, California, focused on developing and commercializing targeted cancer therapies for patients of all ages, with a particular emphasis on pediatric cancers where there is a significant unmet medical need. The company partners with oncologists, families and scientists to identify, acquire and advance important targeted treatments, including a lead program in pediatric low-grade glioma.

Servier is an independent international pharmaceutical group headquartered in France, historically strong in cardiology and venous diseases and aiming to become a leading innovator in oncology and neurology. With more than 20,000 employees, medicines in over 130 countries and €6.9 billion in 2024/25 revenues, Servier is expanding its portfolio in rare cancers and invests nearly 20% of its brand-name sales in R&D.

Average Trading Volume: 2,734,097

Technical Sentiment Signal: Buy

Current Market Cap: $1.35B

Learn more about DAWN stock on TipRanks’ Stock Analysis page.